GLP-1R rs2268641变异增加中国人糖尿病肾病风险

doi:10.16352/j.issn.1001-6325.2025.09.1190

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (9): 1190-1194.doi: 10.16352/j.issn.1001-6325.2025.09.1190

GLP-1R rs2268641变异增加中国人糖尿病肾病风险

何珂¹, 杨帆², 陆西宛¹, 胡蕴^3,4*

1.无锡市中医医院(南京中医药大学附属无锡医院)内分泌科,江苏无锡 214000;
2.盐城市第一人民医院内分泌科,江苏盐城 224008;
3.南京医科大学附属无锡人民医院内分泌科,江苏无锡 214000;
4.南京医科大学附属南京医院内分泌科,江苏南京 210000

收稿日期:2025-01-07 修回日期:2025-04-29 发布日期:2025-08-27
通讯作者: ^*huyunwuxi@163.com
基金资助:
无锡市双百拔尖人才项目(HB2023071);无锡市卫健委青年项目(Q202151)

Variations in GLP-1R rs2268641 increase risk of diabetic nephropathy in China

HE Ke¹, YANG Fan², LU Xiwan¹, HU Yun^3,4*

1. Department of Endocrinology, Wuxi Hospital of Traditional Chinese Medicine, Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi 214000;
2. Department of Endocrinology, Yancheng First Hospital, Yancheng 224008;
3. Department of Endocrinology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214000;
4. Department of Endocrinology, Nanjing Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China

Received:2025-01-07 Revised:2025-04-29 Published:2025-08-27
Contact: ^*huyunwuxi@163.com

摘要/Abstract

摘要： 目的探讨胰高血糖素样肽-1受体(GLP-1R)基因(rs2268641)多态性与糖尿病肾病(DN)发生的相关性。方法纳入490例合并或不合并DN的中国2型糖尿病(T2DM)患者,采用TaqMan等位基因分型对GLP-1R基因多态性进行基因分型。结果 T2DM患者rs2268641的C等位基因与DN之间相关。各基因型尿白蛋白排泄率(UAER)比较,CC纯合子比CT杂合子(P＜0.01)和TT纯合子(P＜0.05)的UAER水平升高,CC纯合子比T等位基因携带者的UAER水平升高(P＜0.05)。单因素logistic回归分析显示,校正了年龄、性别、家族史、空腹血糖和糖化血红蛋白(OR:1.781, 95% CI=1.076~2.947, P＜0.05), CC纯合子患者患DN的几率也高于CT杂合子患者(OR:1.715, 95% CI=1.058~2.778, P＜0.05)。此外,CC纯合子在调校正前(OR:1.585, 95% CI=1.013~2.481, P＜0.05)和校正后(OR:1.660, 95% CI=1.040~2.650, P＜0.05)DN患病率均高于T等位基因携带者。结论证实GLP-1R基因变异,尤其是rs2268641的C等位基因,在中国T2DM患者中增加了患DN的风险。

关键词: 2型糖尿病, 糖尿病肾病, 胰高血糖素样肽-1受体(GLP-1R), 基因多态性

Abstract: Objective To investigate the association between glucagon-like peptide-1 receptor (GLP-1R) gene polymorphism (rs2268641) and the incidence of diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM). Methods A total of 490 T2DM patients with or without DN were included in this project. GLP-1R genetic polymorphisms were genotyped with TaqMan allelic discrimination. Results The C allele of rs2268641 was significantly associated with DN in T2DM patients. As compare to urinary albumin excretion rate(UAER) among genotypes, CC homozygote had a higher level of UAER than CT heterozygous (P＜0.01) and TT homozygote(P＜0.05) respectively. CC homozygote had a higher level of UAER than the carriers of the T allele(P＜0.05). Univariate logistic regression analysis showed that CC homozygote had higher odds for DN than CT heterozygote (OR:1.715, 95% CI=1.058-2.778, P＜0.05), even after adjustment for age, gender, family history, FBG and HbA1c (OR:1.781, 95% CI=1.076-2.947, P＜0.05). Moreover, the CC homozygote had higher odds for DN than the carriers of the T allele before (OR:1.585, 95% CI=1.013-2.481, P＜0.05) and after adjustment (OR:1.660, 95% CI=1.040-2.650, P＜0.05). Conclusions GLP-1R gene variants, especially the C allele of rs2268641 increase the risk of DN in Chinese T2DM patients.

Key words: type 2 diabetes mellitus, diabetic nephropathy, glucagon-like peptide-1 receptor(GLP-1R), genetic polymorphism

中图分类号:

R587.1

何珂, 杨帆, 陆西宛, 胡蕴. GLP-1R rs2268641变异增加中国人糖尿病肾病风险[J]. 基础医学与临床, 2025, 45(9): 1190-1194.

HE Ke, YANG Fan, LU Xiwan, HU Yun. Variations in GLP-1R rs2268641 increase risk of diabetic nephropathy in China[J]. Basic & Clinical Medicine, 2025, 45(9): 1190-1194.

参考文献

[1] Wal P, Tyagi S, Pal RS, et al. A strategic investigation on diabetic nephropathy; Its conceptual model and clinical manifestations: a review[J]. Curr Diabetes Rev, 2023, 19: e260422204036. doi:10.2174/1573399818666220426091238.
[2] 张雅慧,白琼.低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展[J].基础医学与临床,2024,44:114-118.
[3] Song J, Ni J, Yin X. The genetic side of diabetic kidney disease: a review[J]. Int Urol Nephrol, 2023, 55: 335-343.
[4] Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity[J]. Peptides, 2023, 161:170939. doi:10.1016/j.peptides.2023.170939.
[5] Gao W, Liu L, Huh E, et al. Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity[J]. Nat Metab, 2023, 5: 1673-1684.
[6] Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation[J]. Diabetologia, 2023,66:1765-1779.
[7] Panda SP. Role of DPP4 and DPP4i in glucose homeo-stasis and cardiorenal syndrome[J]. Endocr Metab Immune Disord Drug Targets, 2023, 23:179-187.
[8] Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential[J]. Kidney international, 2014,85:579-589. doi:10.1038/ki.2013.427.
[9] Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression[J]. Am J Pathol, 2013,182:132-141.
[10] Zhao X, Liu G, Shen H, et al. Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells[J]. Int J Mol Med, 2015, 35: 684-692.
[11] Hattori S. Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus[J]. Diabetol Metab Syndr, 2021, 13:117. doi:10.1186/s13098-021-00735-3.
[12] Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. New England J Med, 2013, 369:1317-1326.
[13] Zhang L, Zhang W, Tian X. The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases[J]. Int J Neurosci, 2023,133:473-491.
[14] Michałowska J, Miller-Kasprzak E, Seraszek-Jaros A, et al. Association of GLP1R variants rs2268641 and rs6923761 with obesity and other metabolic parameters in a Polish cohort[J]. Front Endocrinol (Lausanne), 2022, 13:1000185. doi:10.3389/fendo.2022.1000185.
[15] Koole C, Wootten D, Simms J, et al. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation[J]. Mole Pharmacol, 2011, 80:486-497.

GLP-1R rs2268641变异增加中国人糖尿病肾病风险

Variations in GLP-1R rs2268641 increase risk of diabetic nephropathy in China

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵青青, 程晓亮. 糖尿病肾病的生物标志物的研究进展[J]. 基础医学与临床, 2025, 45(4): 546-550.
[2]	邓婕, 魏佳莉. 高尿酸血症在糖尿病肾病中的作用[J]. 基础医学与临床, 2025, 45(3): 378-381.
[3]	邹文兵, 王安仙, 曹政媛. 贵阳地区原发性高血压患者降压药物疗效相关基因的多态性[J]. 基础医学与临床, 2024, 44(7): 979-983.
[4]	欧阳碧露, 王国强, 王萌萌, 王秀阁. 2型糖尿病周围神经病变临床预测模型的构建[J]. 基础医学与临床, 2024, 44(12): 1685-1690.
[5]	张雅慧, 白琼. 低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(1): 114-118.
[6]	陈纤纤, 冯烈, 周颖, 董向楠. 糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较[J]. 基础医学与临床, 2023, 43(7): 1097-1103.
[7]	舒玲, 霍本念, 宋林. NT5C2在疾病及治疗中的研究进展[J]. 基础医学与临床, 2023, 43(5): 852-856.
[8]	王玉洁, 杨孟迪, 何风英, 丁雨露, 孙琳楠, 甄东户. 免疫调节基因的多态性与Graves病易感性的相关性研究进展[J]. 基础医学与临床, 2023, 43(3): 495-499.
[9]	王丽妍, 安菲, 刁宗礼, 黄红东, 刘文虎. 多肽Apelin减轻高糖诱导的肾脏足细胞损伤[J]. 基础医学与临床, 2023, 43(12): 1771-1777.
[10]	吕文玥, 李金梦, 李含, 刘雷, 王娜. NR4A1在糖尿病肾病发病中作用的研究进展[J]. 基础医学与临床, 2023, 43(10): 1608-1611.
[11]	田晓怡, 刘颖, 姚瑶, 顾秀丽, 李爱华, 郑胡镛, 宋文琪. 儿童急性淋巴细胞白血病ABCB1、ABCC4和SLCO1B1多态性与大剂量MTX血药浓度及不良反应的相关性[J]. 基础医学与临床, 2022, 42(5): 708-713.
[12]	郑天圣, 佟雪巍, 张伊桐, 朱敏, 詹晓蓉. 2型糖尿病心血管并发症发病机制的研究进展[J]. 基础医学与临床, 2022, 42(5): 814-817.
[13]	郑杨, 魏海军, 申嘉陵, 刘润禹, 刘勇, 孙晓磊. MVBs及IL-1β在2型糖尿病大鼠血管钙化中的作用[J]. 基础医学与临床, 2022, 42(2): 208-214.
[14]	邓九红, 郑超, 王声遥, 王心怡. 醋酸泼尼松对糖尿病肾病模型大鼠肾功能、肾脏炎性反应及AMPK/SIRT1信号通路的影响[J]. 基础医学与临床, 2022, 42(2): 243-248.
[15]	覃意往, 莫梅香, 张龙炯, 罗银亚, 韦良银, 胡季芳, 鲁衍强. 贵州省荔波县汉族和布依族女性MTHFR与MTRR多态性的分布[J]. 基础医学与临床, 2021, 41(5): 694-697.